A reappraisal of Gaucher disease-diagnosis and disease management algorithms.

Creative Commons License

Mistry P. K., Cappellini M. D., Lukina E., Ozsan H., Pascual S. M., Rosenbaum H., ...More

American journal of hematology, vol.86, no.1, pp.110-5, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 86 Issue: 1
  • Publication Date: 2011
  • Doi Number: 10.1002/ajh.21888
  • Journal Name: American journal of hematology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.110-5
  • Dokuz Eylül University Affiliated: Yes


Type 1 (non-neuronopathic) Gaucher disease was the first lysosomal storage disorder for which an effective enzyme replacement therapy was developed and it has become a prototype for treatments for related orphan diseases. There are currently four treatment options available to patients with Gaucher disease, nevertheless, almost 25% of Type 1 Gaucher patients do not gain timely access to therapy because of delays in diagnosis after the onset of symptoms. Diagnosis of Gaucher disease by enzyme testing is unequivocal, but the rarity of the disease and nonspecific and heterogeneous nature of Gaucher disease symptoms may impede consideration of this disease in the differential diagnosis. To help promote timely diagnosis and optimal management of the protean presentations of Gaucher disease, a consensus meeting was convened to develop algorithms for diagnosis and disease management for Gaucher disease.